Vontobel Holding Ltd. Sells 46,675 Shares of Bristol Myers Squibb Company $BMY

Vontobel Holding Ltd. reduced its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,011,674 shares of the biopharmaceutical company’s stock after selling 46,675 shares during the period. Vontobel Holding Ltd.’s holdings in Bristol Myers Squibb were worth $45,626,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its stake in shares of Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of Bristol Myers Squibb in the first quarter valued at approximately $438,000. Caisse DE Depot ET Placement DU Quebec boosted its holdings in Bristol Myers Squibb by 32.9% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,081,939 shares of the biopharmaceutical company’s stock valued at $65,987,000 after acquiring an additional 267,723 shares during the last quarter. Harvest Portfolios Group Inc. boosted its stake in shares of Bristol Myers Squibb by 5.7% in the 1st quarter. Harvest Portfolios Group Inc. now owns 985,650 shares of the biopharmaceutical company’s stock valued at $60,115,000 after purchasing an additional 53,005 shares during the last quarter. Finally, PKS Advisory Services LLC grew its holdings in Bristol Myers Squibb by 7.1% during the 1st quarter. PKS Advisory Services LLC now owns 5,757 shares of the biopharmaceutical company’s stock worth $349,000 after acquiring an additional 384 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BMY. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their price target for the company from $52.00 to $61.00 in a research note on Monday, December 15th. Wells Fargo & Company increased their target price on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. The Goldman Sachs Group reissued a “neutral” rating and issued a $57.00 price target (up previously from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Finally, Truist Financial set a $65.00 target price on Bristol Myers Squibb in a report on Wednesday, December 3rd. Six investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $54.62.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Multiple recent deep-dive pieces argue BMY is materially undervalued (forward P/E ~8x vs. sector ~19.5x), point to a growth portfolio now contributing ~57% of revenue, strong margins, cash flow and a 4.65% dividend yield — a clear bullish case for value investors. Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over – It’s Not
• Positive Sentiment: Other year‑end analyses highlight BMY’s rebound and argue the stock still looks undervalued despite recent gains, reinforcing momentum-driven buying interest. Bristol-Myers Squibb Surges Into Year-End: Why BMY Still Looks Undervalued
• Neutral Sentiment: Analyst consensus remains “Hold” — confirming the market sees limited near‑term upside from upgrades but also no widespread downgrades; this tends to temper rallies. Bristol Myers Squibb Company (NYSE:BMY) Given Consensus Recommendation of “Hold” by Analysts
• Neutral Sentiment: BMO (covered via TipRanks) maintained a Hold citing stable cash flows offset by a slower ramp for Cobenfy — supports a cautious view on near-term growth. Bristol-Myers Squibb: Stable Cash Flows Offset by Slower Cobenfy Ramp Support Hold Rating
• Neutral Sentiment: Coverage in mainstream outlets (Yahoo Finance) is asking whether BMY is still undervalued after its rebound — these pieces can sustain retail interest but don’t change fundamentals immediately. Is Bristol Myers Squibb (BMY) Still Undervalued After Its Recent Share Price Rebound?
• Negative Sentiment: BMY agreed to supply Eliquis to Medicaid patients at no cost starting in 2026 and to donate seven tons of the active ingredient — a potential headwind to U.S. Eliquis sales and near‑term revenue. Bristol-Myers (BMY) Offers Eliquis Free to Medicaid Patients Under New Pricing Pact
• Negative Sentiment: Analysts and coverage (Zacks) are flagging uncertainty about how much the pricing deal will dent sales — introduces execution risk and potential margin pressure in 2026. Will the Recent Pricing Deal With the Government Impact BMY’s Sales?
• Negative Sentiment: Earlier coverage warned “tricky tests lie ahead” (clinical and commercial execution risks), a reminder that pipeline and trial readouts remain potential catalysts for downside. Bristol-Myers Squibb: Recent Gains Impress, But Tricky Tests Lie Ahead

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $54.37 on Wednesday. The company has a fifty day moving average price of $48.16 and a 200 day moving average price of $47.22. The firm has a market cap of $110.69 billion, a PE ratio of 18.37, a PEG ratio of 8.37 and a beta of 0.29. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same period in the previous year, the company posted $1.80 earnings per share. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.6%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is 83.78%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.